| First Author | Singh A | Year | 2021 |
| Journal | Semin Cancer Biol | Volume | 70 |
| Pages | 71-84 | PubMed ID | 32479952 |
| Mgi Jnum | J:303814 | Mgi Id | MGI:6508625 |
| Doi | 10.1016/j.semcancer.2020.05.014 | Citation | Singh A, et al. (2020) Microbiome and host crosstalk: A new paradigm to cancer therapy. Semin Cancer Biol |
| abstractText | The commensal microbiome of humans has co-evolved for thousands of years. The microbiome regulates human health and is also linked to several diseases, including cancer. The advances in next-generation sequencing have significantly contributed to our understanding of the microbiome and its association with cancer and cancer therapy. Recent studies have highlighted a close relationship of the microbiome to the pharmacological effect of chemotherapy and immunotherapy. The chemo-drugs usually interfere with the host immune system and reduces the microbiome diversity inside the body, which in turn leads to decreased efficacy of these drugs. The human microbiome, specifically the gut microbiome, increases the potency of chemo-drugs through metabolism, enzymatic degradation, ecological differences, and immunomodulation. Recent research exploits the involvement of microbiome to shape the efficacy and decrease the toxicity of these chemo-drugs. In this review, we have highlighted the recent development in understanding the relationship of the human microbiome with cancer and also emphasize on various roles of the microbiome in the modulation of cancer therapy. Additionally, we also summarize the ongoing research focussed on the improved efficacy of chemotherapy and immunotherapy using the host microbiome. |
